MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

A

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

Search

Microbot Medical Inc

Fermé

2.41 5.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.25

Max

2.44

Chiffres clés

By Trading Economics

Revenu

-77K

-3.6M

Employés

20

EBITDA

-79K

-3.6M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+211.2% upside

Dividendes

By Dow Jones

Prochains Résultats

12 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

29M

169M

Ouverture précédente

-2.83

Clôture précédente

2.41

Score Technique

By Trading Central

Confiance

Neutral Evidence

Microbot Medical Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Nike, RH, NCino

31 mars 2026, 22:35 UTC

Résultats

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 avr. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mars 2026, 23:50 UTC

Acquisitions, Fusions, Rachats

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mars 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mars 2026, 23:21 UTC

Résultats

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mars 2026, 23:14 UTC

Market Talk
Résultats

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mars 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss Widens >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mars 2026, 21:46 UTC

Acquisitions, Fusions, Rachats

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mars 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mars 2026, 21:35 UTC

Résultats

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mars 2026, 21:33 UTC

Résultats

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mars 2026, 21:32 UTC

Résultats

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mars 2026, 21:28 UTC

Résultats

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mars 2026, 21:26 UTC

Résultats

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mars 2026, 21:25 UTC

Résultats

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mars 2026, 21:24 UTC

Market Talk
Résultats

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mars 2026, 21:22 UTC

Résultats

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mars 2026, 21:22 UTC

Résultats

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mars 2026, 21:21 UTC

Résultats

Nike's Digital Channel Still Too Promotional, CFO Says

31 mars 2026, 21:20 UTC

Résultats

Nike CEO: Converse Remains Important to Portfolio

Comparaison

Variation de prix

Microbot Medical Inc prévision

Objectif de Prix

By TipRanks

211.2% hausse

Prévisions sur 12 Mois

Moyen 7.5 USD  211.2%

Haut 12 USD

Bas 5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.52 / 2.57Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat